Seaport Therapeutics, Inc. (SPTX)

Seaport Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2024
Cash & Equivalents	46.04	309.1
Short-Term Investments	169.94	-
Cash & Short-Term Investments	215.98	309.1
Cash Growth	-30.13%	-
Other Current Assets	7.25	1.05
Total Current Assets	223.23	310.15
Net Property, Plant & Equipment	5.23	5.17
Long-Term Investments	17.67	-
Other Long-Term Assets	2.88	0.45
Total Assets	249.01	315.78
Accounts Payable	2.01	5.08
Accrued Expenses	9.13	5.21
Current Portion of Leases	1.64	0.86
Total Current Liabilities	12.78	11.15
Long-Term Leases	3.44	4.15
Total Long-Term Liabilities	3.44	4.15
Total Liabilities	16.23	15.3
Common Stock	0	0
Additional Paid-in Capital	21.26	14.38
Accumulated Other Comprehensive Income	0.3	-
Retained Earnings	-114.11	-39.23
Total Common Shareholders' Equity	-92.55	-24.85
Minority Interest	325.33	325.33
Shareholders' Equity	232.78	300.48
Total Liabilities & Equity	249.01	315.78

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q